Page 92 - Mesenchymal Stem cells, Exosomes and vitamins in the fight aginst COVID

Intravascular Mesenchymal Stem Cells to Treat Organ Failure and Possible Application in COVID-19

Mean daily hepatic growth rates were 2.5-fold higher when contrasted with a comparable group. SS improvement in albumin and total decrease in ascites and improvement in P111P levels implying decrease in liver fibrosis when followed for 6 months. Improvement in LFTs and MELD score and the SF-36 mean physical and mental component scores. and INR levels. bilirubin levels. improved for 3–36 weeks. ALB and total protein and prothrombin time

Findings proteins and Child Pugh scores along with AFP and PCNA expression based on liver bx reflecting liver regeneration. Decreased Mild improvement in bilirubin, albumin, Child Pugh score/albumin decreased max at 3 months but no change by 12 months and no change in the MELD. No change in ALB levels increased up to 6 months. TBIL and PT were better for 4–12 weeks. MELD score. No change in liver fibrosis markers. increased for 4 weeks. T

Condition Post liver resection Cirrhosis Cirrhosis CLD Cirrhosis Hepatitis B liver failure Cirrhosis Cirrhosis

Follow-Up (months) 26 days 6 12 4 12 6 6 12

Result Yes Yes Yes Yes Yes Yes Yes Yes

Delivery Method PVI IV IV HAI HAI HAI IV IV

Type of Stem Cell BM MNC BM MNC BM MSC (Pas 2–4) BM MNC BM MNC BM MSC [Pas 3] BM MNC WJ MSC (Pas 3–4)

Number of SC 2.4–12.3 million 5.2 billion 31 million 100 million 378 million 340 million 8 billion 0.5 million/ kg

BMA (mL) 60–220 400 80–100 50 50 100–120 400 NA

Table 3. MSC therapy studies treating liver failure.
No. of Patients in Treatment Group 3 9 4 10 15 53 5 30

Type of Study PCT Case series Case series Case series RCT PCT PCT PCT

Year 2005 2006 2007 2007 2010 2011 2011 2012

Author Esch et al, Stem Cells 2005; 23:463-470 Terai et al, Stem Cells 2006; 24:2292-2298 Mohamadnejad et al, Arch Iran Med 2007; 10:459-466 Lyra et al, World J Gastroenterol 2007; 13:1067-1073 Lyra et al, Eur J Gastroenterol Hepatol 2010; 22:33-42 Peng et al, Hepatology 2011; 54:820-828 Saito et al, Stem Cells Dev 2011; 20:1503-1510 Zhang et al, J Gastroenterol Hepatol 2012; 27(suppl 2):112-120

www.painphysicianjournal.com S409